Tuesday, September 29, 2020 6:18:58 PM
Dow Jones 9/29/20 9:31 AM ET
CHARLOTTESVILLE, VA / ACCESSWIRE / September 29, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that the U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for the Assure/FaStep(R) COVID-19 IgG/IgM Rapid Test Device. This marks the first FDA EUA for a serology (antibody) point-of-care (POC) test for COVID-19 using fingerstick blood samples as compared with current approved tests that only utilize serum, plasma, or a venous blood draw. See the FDA news release here.
As a result of the FDA's EUA, fingerstick blood samples can now be utilized with the FaStep COVID-19 IgG/IgM Rapid Test Device for the test in POC settings, including doctors' offices, hospitals, urgent care centers, emergency rooms, or other locations where there is a licensed healthcare professional. The FaStep COVID-19 IgG/IgM Rapid Test Device was initially authorized for emergency use in July 2020 to help identify individuals with antibodies to SARS-CoV-2, indicating recent or prior COVID-19 infection, but as with all competing rapid COVID-19 test kits, was not yet authorized for fingerstick blood sample use.
Adial has commenced sales of the FaStep COVID-19 IgG/IgM rapid antibody test kits to healthcare providers and hospitals through The iRemedy Healthcare Companies, Inc. (iRemedy) network and ecommerce platform. See here. Antibody test kits distributed by Adial are lateral flow assay, 10-minute, 'instant' point-of-care test devices for the qualitative detection of lgG and lgM antibodies specific to SARS-CoV-2 virus in fingerstick whole blood, venous whole blood, serum, and plasma. During testing, the specimen reacts with antigen coated particles in the test cassette after droplets of blood from the subject are placed on the cassette's coated membrane.
William Stilley, Chief Executive Officer of Adial Pharmaceuticals, commented, "The issuance of the EUA for the first point-of-care antibody test for COVID-19 in the U.S. using fingerstick blood samples is expected to provide an important competitive advantage, which should support more widespread adoption of the Assure/FaStep COVID-19 IgG/IgM Rapid Test Device as a fast, convenient and reliable method for COVID-19 serology testing. We see a market demand for these instant and efficient antibody tests to help combat the international COVID-19 pandemic with the addressable global COVID-19 rapid test kits market expected to reach $3.52 billion by the end of 2020."
https://ir.adialpharma.com/press-releases/detail/94/adial-pharmaceuticals-announces-covid-19-point-of-care
Recent ADIL News
- Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder • GlobeNewswire Inc. • 09/19/2024 12:30:00 PM
- Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/04/2024 01:00:00 PM
- Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:13:57 PM
- Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04 • GlobeNewswire Inc. • 08/13/2024 01:00:00 PM
- Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder • GlobeNewswire Inc. • 08/07/2024 01:00:00 PM
- Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044 • GlobeNewswire Inc. • 07/31/2024 12:30:00 PM
- Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder • GlobeNewswire Inc. • 07/23/2024 12:30:00 PM
- Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder • GlobeNewswire Inc. • 06/20/2024 12:30:00 PM
- Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder • GlobeNewswire Inc. • 06/05/2024 12:30:00 PM
- Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th • GlobeNewswire Inc. • 05/29/2024 12:30:00 PM
- Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/15/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:03:18 PM
- Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office • GlobeNewswire Inc. • 04/22/2024 12:30:00 PM
- Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder • GlobeNewswire Inc. • 04/10/2024 12:30:00 PM
- Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update • GlobeNewswire Inc. • 04/02/2024 12:30:00 PM
- Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds • GlobeNewswire Inc. • 03/02/2024 12:00:00 AM
- Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office • GlobeNewswire Inc. • 02/28/2024 02:30:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:22:13 PM
- Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office • GlobeNewswire Inc. • 02/13/2024 02:15:24 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/25/2024 09:30:56 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/25/2024 05:15:07 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:15:23 PM
- Adial Announces Appointment of Tony Goodman as Chief Operating Officer • GlobeNewswire Inc. • 01/18/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:17:10 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM